Bullfrog AI Holdings Inc Dossier
Qualitative Analysis
Business overview
BullFrog AI Holdings, Inc. is a digital biopharmaceutical technology company that leverages artificial intelligence (AI) and machine learning (ML) to analyze complex biomedical datasets. The company's core mission is to streamline therapeutics development, identify novel drug targets, discover biomarkers, and reduce clinical trial failure rates. Its proprietary technology suite centers on the bfLEAP™ platform, an explainable AI engine originally developed at the Johns Hopkins University Applied Physics Laboratory and exclusively licensed to BullFrog AI. In early 2026, the company completed its end-to-end pharmaceutical R&D platform by launching bfARENAS™ (joining bfPREP™ and bfLEAP™), enabling a continuous workflow from raw data harmonization to strategic decision-making.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Expanding the commercial pipeline for the company's fully integrated end-to-end AI stack (comprising bfPREP™, bfLEAP®, and bfARENAS™) by targeting global pharmaceutical and biotechnology partners.
Expected impact: Aims to secure multi-year enterprise partnerships, generate recurring licensing and milestone-based revenues, and establish the platform as an industry standard for R&D decision-making.
Appointed a new commercial management team (including John Stewart, Eric Roos, and Tom Hazel) to drive commercial sales, business development, corporate strategy, and scientific operations.
Expected impact: Accelerates the translation of scientific capabilities into commercial contracts and expands the global pipeline for the integrated AI platforms.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides high-profile third-party validation of the bfLEAP® platform in neuropsychiatry and embeds BullFrog AI's technology into an active drug discovery program for major depressive disorder.
Terms: Includes milestone-based payments tied to specific deliverables and an option for the client to secure exclusive rights to a selected final target candidate for three years.
Applies BullFrog's AI solutions to Eleison's Phase 3 pancreatic cancer drug, glufosfamide, to identify patient subgroups and biomarkers, demonstrating real-world clinical utility.
Terms: Financial terms not disclosed; Eleison is exploring follow-on collaborations based on successful initial results presented at ASCO GI 2026.
Joint sales and marketing launch of BullFrog Data Networks to co-promote AI-driven drug discovery and data preparation services.
Terms: Expected to generate collaborative revenue through 2028.